These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7730906)

  • 41. One-sided sequential stopping boundaries for clinical trials: a decision-theoretic approach.
    Berry DA; Ho CH
    Biometrics; 1988 Mar; 44(1):219-27. PubMed ID: 3358990
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Monitoring boundaries for adverse effects in long-term clinical trials.
    Lan KK; Friedman L
    Control Clin Trials; 1986 Mar; 7(1):1-7. PubMed ID: 3956208
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The quest for "power": contradictory hypotheses and inflated sample sizes.
    Feinstein AR; Concato J
    J Clin Epidemiol; 1998 Jul; 51(7):537-45. PubMed ID: 9674660
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Shortening the PHQ-9: a proof-of-principle study of utilizing Stochastic Curtailment as a method for constructing ultrashort screening instruments.
    Smits N; Finkelman MD
    Gen Hosp Psychiatry; 2015; 37(5):464-9. PubMed ID: 26026647
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Exact and asymptotic inference in clinical trials with small event rates under inverse sampling.
    Heimann G; Von Tress M; Gasparini M
    Stat Med; 2015 Aug; 34(19):2708-24. PubMed ID: 25872880
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimization of adaptive designs: efficiency evaluation.
    Menon S; Chang M
    J Biopharm Stat; 2012; 22(4):641-61. PubMed ID: 22651106
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interim analysis for randomized clinical trials: simulating the predictive distribution of the log-rank test statistic.
    Chang MN; Shuster JJ
    Biometrics; 1994 Sep; 50(3):827-33. PubMed ID: 7981402
    [TBL] [Abstract][Full Text] [Related]  

  • 48. How reliable are clinical trials? The importance of the criteria for early termination.
    Schwartz PJ
    Eur Heart J; 1995 Aug; 16 Suppl G():37-45. PubMed ID: 8595799
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A general inefficacy interim monitoring rule for randomized clinical trials.
    Freidlin B; Korn EL; Gray R
    Clin Trials; 2010 Jun; 7(3):197-208. PubMed ID: 20423925
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Statistical interim monitoring of the Cardiac Arrhythmia Suppression Trial.
    Pawitan Y; Hallstrom A
    Stat Med; 1990 Sep; 9(9):1081-90. PubMed ID: 2244080
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Stochastic optimization of adaptive enrichment designs for two subpopulations.
    Fisher A; Rosenblum M;
    J Biopharm Stat; 2018; 28(5):966-982. PubMed ID: 30095330
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Frequentist evaluation of group sequential clinical trial designs.
    Emerson SS; Kittelson JM; Gillen DL
    Stat Med; 2007 Dec; 26(28):5047-80. PubMed ID: 17573678
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Monitoring a clinical trial with multiple hypotheses concerning the treatment effect on a single primary endpoint.
    Denne JS; Koch GG
    Stat Med; 2001 Oct; 20(19):2801-12; discussion 2813-4. PubMed ID: 11568939
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Conditional power calculations for early acceptance of H0 embedded in sequential tests.
    Betensky RA
    Stat Med; 1997 Feb; 16(4):465-77. PubMed ID: 9044533
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Monitoring clinical trials: conditional or predictive power?
    Spiegelhalter DJ; Freedman LS; Blackburn PR
    Control Clin Trials; 1986 Mar; 7(1):8-17. PubMed ID: 3956212
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Issues in designing sequential stopping rules for monitoring side effects in clinical trials.
    Goldman AI
    Control Clin Trials; 1987 Dec; 8(4):327-37. PubMed ID: 3327653
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Increasing the sample size at interim for a two-sample experiment without Type I error inflation.
    Dunnigan K; King DW
    Pharm Stat; 2010; 9(4):280-7. PubMed ID: 19764040
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interim analyses of survival data in cancer clinical trials.
    Skovlund E
    Acta Oncol; 1998; 37(7-8):645-50. PubMed ID: 10050981
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
    Taylor DJ; Grobler A; Abdool Karim SS
    Clin Trials; 2012 Aug; 9(4):377-84. PubMed ID: 22610168
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Conditional power calculations as an aid in the decision whether to continue a clinical trial.
    Andersen PK
    Control Clin Trials; 1987 Mar; 8(1):67-74. PubMed ID: 3568698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.